# Amneal Pharmaceuticals Inc. (AMRX)

Source: https://www.quantisnow.com/company/AMRX
Generated: 2026-11-16T04:34:19.044Z

- Ticker: AMRX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001723128
- Website: amneal.com

## About

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed, owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinson's disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.

## Latest AMRX news and filings

- 2026-11-10 21:02 UTC [Amneal Named BioSpace 2027 Best Place to Work, Ranking No.1 Among Large Employers](https://www.quantisnow.com/insight/amneal-named-biospace-2027-best-place-to-work-ranking-no1-6783759)
- 2026-11-10 09:48 UTC [FDA Approval for FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE issued to IMPAX PHARMS](https://www.quantisnow.com/insight/fda-approval-for-fexofenadine-hydrochloride-and-pseudoephedrine-hydrochloride-issued-to-6782406)
- 2026-11-10 09:48 UTC [FDA Approval for ISOTRETINOIN issued to AMNEAL PHARMS NY](https://www.quantisnow.com/insight/fda-approval-for-isotretinoin-issued-to-amneal-pharms-ny-6782404)
- 2026-11-10 09:48 UTC [FDA Approval for ISOTRETINOIN issued to AMNEAL PHARMS NY](https://www.quantisnow.com/insight/fda-approval-for-isotretinoin-issued-to-amneal-pharms-ny-6782403)
- 2026-11-09 21:21 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-amneal-pharmaceuticals-inc-6781591)
- 2026-11-04 10:26 UTC [FDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMS](https://www.quantisnow.com/insight/fda-approval-for-mometasone-furoate-issued-to-amneal-pharms-6770894)
- 2026-11-04 10:26 UTC [FDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMS](https://www.quantisnow.com/insight/fda-approval-for-mometasone-furoate-issued-to-amneal-pharms-6770893)
- 2026-11-04 10:26 UTC [FDA Approval for MOMETASONE FUROATE issued to AMNEAL PHARMS](https://www.quantisnow.com/insight/fda-approval-for-mometasone-furoate-issued-to-amneal-pharms-6770892)
- 2026-11-04 10:18 UTC [FDA Approval for CYCLOPHOSPHAMIDE issued to AMNEAL PHARMS](https://www.quantisnow.com/insight/fda-approval-for-cyclophosphamide-issued-to-amneal-pharms-6770891)
- 2026-11-04 10:18 UTC [FDA Approval for GUAIFENESIN issued to AMNEAL PHARMS](https://www.quantisnow.com/insight/fda-approval-for-guaifenesin-issued-to-amneal-pharms-6770888)
- 2026-11-03 13:07 UTC [SEC Form 8-K] [Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amneal-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6768538)
- 2026-11-03 11:00 UTC [Earnings] [Amneal Reports Third Quarter 2026 Financial Results](https://www.quantisnow.com/insight/amneal-reports-third-quarter-2026-financial-results-6768115)
- 2026-10-23 20:05 UTC [SEC Form 8-K] [Amendment: SEC Form 8-K/A filed by Amneal Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-8-ka-filed-by-amneal-pharmaceuticals-inc-6756275)
- 2026-10-08 12:00 UTC [Earnings Date] [Amneal to Report Third Quarter 2026 Results on November 3, 2026](https://www.quantisnow.com/insight/amneal-to-report-third-quarter-2026-results-on-november-3-6741096)
- 2026-09-23 12:33 UTC [Analyst Coverage Initiated] [Oppenheimer initiated coverage on Amneal Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/oppenheimer-initiated-coverage-on-amneal-pharmaceuticals-with-a-new-price-6723765)
- 2026-09-21 20:33 UTC [SEC Form 4] [Director Buchi J Kevin gifted 20,445 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-buchi-j-kevin-gifted-20445-shares-sec-form-4-6721837)
- 2026-09-18 20:01 UTC [Amneal Announces FDA Approval and Launch of Lanreotide Injection](https://www.quantisnow.com/insight/amneal-announces-fda-approval-and-launch-of-lanreotide-injection-6720401)
- 2026-09-14 20:10 UTC [SEC Form 4] [Director Buchi J Kevin exercised 20,445 shares at a strike of $14.45, increasing direct ownership by 27% to 95,522 units (SEC Form 4)](https://www.quantisnow.com/insight/director-buchi-j-kevin-exercised-20445-shares-at-a-strike-6714465)
- 2026-09-09 13:22 UTC [Analyst Coverage Initiated] [Leerink Partners initiated coverage on Amneal Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/leerink-partners-initiated-coverage-on-amneal-pharmaceuticals-with-a-new-6709636)
- 2026-09-03 20:44 UTC [SEC Form S-3ASR] [SEC Form S-3ASR filed by Amneal Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-3asr-filed-by-amneal-pharmaceuticals-inc-6705479)
- 2026-09-02 21:03 UTC [SEC Form 4] [Executive Vice President Boyer Andrew S gifted 80,000 shares, decreasing direct ownership by 29% to 193,646 units (SEC Form 4)](https://www.quantisnow.com/insight/executive-vice-president-boyer-andrew-s-gifted-80000-shares-decreasing-6703625)
- 2026-08-25 20:41 UTC [SEC Form 4] [Executive Vice President Boyer Andrew S gifted 152,426 shares, decreasing direct ownership by 36% to 273,646 units (SEC Form 4)](https://www.quantisnow.com/insight/executive-vice-president-boyer-andrew-s-gifted-152426-shares-decreasing-6694469)
- 2026-08-14 20:29 UTC [SEC Form 4] [Director Kiely John sold $882,000 worth of shares (50,000 units at $17.64) and gifted 10,000 shares, decreasing direct ownership by 23% to 200,252 units (SEC Form 4)](https://www.quantisnow.com/insight/director-kiely-john-sold-882000-worth-of-shares-50000-units-6683196)
- 2026-08-13 20:22 UTC [SEC Form 4] [Executive Vice President Shah Nikita sold $2,563,517 worth of shares (146,403 units at $17.51), decreasing direct ownership by 37% to 253,390 units (SEC Form 4)](https://www.quantisnow.com/insight/executive-vice-president-shah-nikita-sold-2563517-worth-of-shares-6680763)
- 2026-08-13 20:21 UTC [SEC Form 4] [EVP, Chief Legal Officer Daly Jason B. sold $3,771,050 worth of shares (216,613 units at $17.41), decreasing direct ownership by 86% to 35,171 units (SEC Form 4)](https://www.quantisnow.com/insight/evp-chief-legal-officer-daly-jason-b-sold-3771050-worth-6680762)
- 2026-08-13 20:21 UTC [SEC Form 4] [SEC Form 4 filed by Director Buchi J Kevin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-buchi-j-kevin-6680736)
- 2026-08-12 22:06 UTC [SEC Form 4] [Large owner Patel Tushar Bhikhubhai was granted 12,763,469 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-patel-tushar-bhikhubhai-was-granted-12763469-shares-sec-6678729)
- 2026-08-12 20:46 UTC [SEC Form 4] [Co-CEO Patel Chintu was granted 6,381,734 shares (SEC Form 4)](https://www.quantisnow.com/insight/co-ceo-patel-chintu-was-granted-6381734-shares-sec-form-4-6678356)
- 2026-08-12 20:39 UTC [SEC Form 4] [Director Patel Gautam was granted 283,632 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-patel-gautam-was-granted-283632-shares-sec-form-4-6678284)
- 2026-08-12 20:37 UTC [SEC Form 4] [President & Co-CEO Patel Chirag K. was granted 6,381,734 shares (SEC Form 4)](https://www.quantisnow.com/insight/president-co-ceo-patel-chirag-k-was-granted-6381734-shares-sec-6678275)
- 2026-08-11 16:32 UTC [SEC Form 144] [SEC Form 144 filed by Amneal Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-144-filed-by-amneal-pharmaceuticals-inc-6675421)
- 2026-08-10 20:05 UTC [SEC Form 8-K] [Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amneal-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6673606)
- 2026-08-10 12:00 UTC [Amneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar Leader](https://www.quantisnow.com/insight/amneal-completes-acquisition-of-kashiv-biosciences-creating-a-global-biosimilar-6672767)
- 2026-08-06 21:19 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-amneal-pharmaceuticals-inc-6670042)
- 2026-08-03 20:28 UTC [SEC Form 8-K] [Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation](https://www.quantisnow.com/insight/amneal-pharmaceuticals-inc-filed-sec-form-8-k-entry-into-a-6660065)
- 2026-07-31 20:08 UTC [SEC Form 8-K] [Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/amneal-pharmaceuticals-inc-filed-sec-form-8-k-submission-of-matters-6657825)
- 2026-07-30 10:43 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Amneal Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-amneal-pharmaceuticals-inc-6654735)
- 2026-07-30 10:15 UTC [SEC Form 8-K] [Amneal Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/amneal-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6654678)
- 2026-07-17 12:00 UTC [Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations](https://www.quantisnow.com/insight/amneal-expands-iohexol-injection-portfolio-with-us-fda-approval-of-6640522)
- 2026-07-09 20:05 UTC [Earnings Date] [Amneal to Report Second Quarter 2026 Results on July 30, 2026](https://www.quantisnow.com/insight/amneal-to-report-second-quarter-2026-results-on-july-30-6632956)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/AMRX
- Earnings history: https://www.quantisnow.com/earnings/AMRX
- Dividend history: https://www.quantisnow.com/dividends/AMRX
- Insider transactions: https://www.quantisnow.com/insiders/AMRX
- Options chain: https://www.quantisnow.com/options/AMRX
- SEC 8-K filings only: https://www.quantisnow.com/company/AMRX/8-k
- RSS and alerts for AMRX: https://www.quantisnow.com/docs/rss-feeds.md
